Bachem Holding AG Stock Swiss Exchange
Equities
BANB
CH0012530207
Biotechnology & Medical Research
Sales 2024 * | 620M 678M | Sales 2025 * | 811M 887M | Capitalization | 6.08B 6.65B |
---|---|---|---|---|---|
Net income 2024 * | 127M 139M | Net income 2025 * | 160M 175M | EV / Sales 2024 * | 9.7 x |
Net cash position 2024 * | 64.89M 70.96M | Net Debt 2025 * | 74.85M 81.84M | EV / Sales 2025 * | 7.59 x |
P/E ratio 2024 * |
50.6
x | P/E ratio 2025 * |
38.4
x | Employees | 2,006 |
Yield 2024 * |
1.06% | Yield 2025 * |
1.15% | Free-Float | 94.31% |
Latest transcript on Bachem Holding AG
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 18-12-31 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 12-04-24 |
Director/Board Member | 51 | 11-04-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 18 M€ | +3.79% | - |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |